Midwest Trust Co Decreases Position in Teva Pharmaceutical Industries Ltd. $TEVA

Midwest Trust Co lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 24.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,239 shares of the company’s stock after selling 17,171 shares during the quarter. Midwest Trust Co’s holdings in Teva Pharmaceutical Industries were worth $1,075,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in TEVA. Phoenix Financial Ltd. increased its holdings in Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the period. Menora Mivtachim Holdings LTD. grew its position in shares of Teva Pharmaceutical Industries by 31.9% in the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after buying an additional 9,303,978 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after buying an additional 4,306,363 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 13.6% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock valued at $658,161,000 after acquiring an additional 3,896,790 shares in the last quarter. Finally, Lingotto Investment Management LLP raised its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the second quarter. Lingotto Investment Management LLP now owns 28,156,918 shares of the company’s stock valued at $471,910,000 after acquiring an additional 302,975 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $34.29 on Thursday. The company has a market capitalization of $39.32 billion, a price-to-earnings ratio of 28.57, a price-to-earnings-growth ratio of 1.96 and a beta of 0.70. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The company’s 50-day moving average is $31.86 and its 200 day moving average is $24.24.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on TEVA shares. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. The Goldman Sachs Group raised their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.11.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer owned 5,650 shares of the company’s stock, valued at approximately $170,630. The trade was a 68.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider directly owned 52,828 shares in the company, valued at approximately $1,517,748.44. The trade was a 80.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 422,060 shares of company stock worth $12,254,965 over the last three months. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.